Analogic mobile CT scanner gets FDA nod
Analogic has received 510(k) marketing clearance from the Food and Administration for Anatom2000, the company's mobile CT scanner. Analogic, of Peabody, MA,will begin the first shipments of the scanner this summer, withfull production beginning in fiscal
Analogic has received 510(k) marketing clearance from the Food and Administration for Anatom2000, the company's mobile CT scanner. Analogic, of Peabody, MA,will begin the first shipments of the scanner this summer, withfull production beginning in fiscal 1996, the company said.
Analogic has signed on Philips and Hitachi as OEM partnersfor Anatom 2000. Philips displayed the scanner as Tomoscan SR32000M at its booth at the Radiological Society of North Americameeting (SCAN 12/14/94). Sales in China and Russia will be handledby Analogic's own joint ventures.
Analogic manufactures data conversion and signal-processinginstruments and systems for many medical imaging OEMs. At theRSNA meeting, the company unveiled DASM-Rx, a family of connectivityproducts designed to improve print management for hospitals witholder medical imaging equipment. DASM-Rx permits remote site diagnosis,referral hard copy prints and film archiving for DICOM-compatibleand non-DICOM systems.
In other Analogic news, the company last month announced thatBruce R. Rusch has been named president and COO, assuming responsibilitiesfor Analogic's day-to-day operations. Rusch's previous title wascorporate vice president.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
